While classical histopathologic approaches are invaluable in classifying tumors and understanding aspects of cellular interactions, genomic approaches provide a means to molecularly dissect tumorigenesis. The relationship of gene expression to the development of neoplasia remains an area of intensive research. With the advent of large-scale genomic platforms, alterations in gene expression can be related to the morphological development of cancer. The feasibility of using large-scale genomic analysis platforms has dramatically changed the landscape of biological sciences, as cellular processes must be considered in the context of complex networks. Alterations in gene expression must now be understood in a systems approach in which the relationships between genes expression changes are studied by considering the interplay of multiple regulatory networks. Ultimately, such changes must be understood at the protein level. We have begun to apply this technology to determine changes in gene expression that differentiate various types of mammary cancers that arise in mouse models that have been initiated by different genetic alterations. Ultimately, a molecular catalogue of similarities and differences between rodent and human tumors can be created which will serve to validate or credential particular models for specific experimental purposes, such as preclinical testing. These approaches have led to new insights into molecular pathways involved in oncogenesis, new classifications of human breast cancer, and the identification of new genes that may be relevant to understanding and treating human cancer. acid; Tag, simian virus 40 T-antigen.
INTRODUCTION
Animal models have been essential components of toxicology studies, yet many questions remain regarding the relevance of animal models for predicting biologic responses in humans. Major differences exist in drug metabolizing pathways between rodents and humans that alter the kinetics of drug distribution and excretion as well as the availability of compounds and their metabolites. Additional physiologic differences exist between rodent and humans that may further complicate the evaluation of potential toxicologic effects of compounds. While detailed histopathologic analyses of the effects of compounds on target tissues in rodents has provided tremendous insights into toxicologic and carcinogenic effects of many compounds, additional understandings of pathologic changes on a molecular level will further define the toxicologic effects of chemicals and drugs. The application of large-scale genomic analyses for further defining molecular mechanisms of carcinogenesis and toxicology are proving to be extremely valuable.
The development of advanced genomic technologies provides the opportunity to characterize on a large scale the molecular characteristics of the rodent models which are used and their responses to various compounds. Ultimately, a thorough comparison between responses identified in rodents with those in humans will lead to a more precise understand-ing of the predictive values and limitations of rodent models for carcinogenesis and toxicology studies.
In an effort to begin to define such parameters, our laboratory has begun to characterize large scale genomic changes that occur in several important models of mammary oncogenesis through the use of comparative genomic hybridization (CGH); (Liu et al., 1998) and gene expression profiling using microarray technologies . Array approaches can be applied to many important basic science and translational questions (Table 1) .
A particular power of transgenic models of cancer is that the initiating oncogenic abnormality has been designed into the construction of the genetically modified animal. The models used in this study overexpressed the myc and her2/neu oncogenes, which are often amplified and/or overexpressed in a significant proportion of human breast cancers (Berns et al., 1992; Liao and Dickson, 2000) . Although the ras oncogene is not directly mutated and activated in human breast cancers (Rochlitz et al., 1989) , the ras pathway is often activated due to the increased signaling initiated through other growth factor/receptor signaling pathways (Wang et al., 1997) . The viral oncogene polyoma middle T antigen (PyMT) is known to activate src signaling (Courtneidge, 1985) , which can be transduced through the ras pathway. In addition, PyMT transgenic mice develop extremely aggressive mammary tumors which demonstrate a high incidence of metastasis to the lungs (Guy et al., 1992) .
The p53 and Rb pathways are known to be important modulators of cell proliferation (Allred et al., 1993; Band, 1998) . Rb may additionally regulate cellular differentiation, whereas p53 is a critical regulator of the cellular response to DNA damage and apoptosis. In particular, p53 mutations have been identified as the genetic abnormality in the Li-Fraumini syndrome in which there is a high incidence of breast cancer (Mietz et al., 1992) . Mutations in p53 have also been identified in a large percentage of sporadic breast cancers (Coles et al., 1992) . For these reasons, we also have utilized two mammary cancer models which overexpress the early region of the SV40 virus that produces large-T and small-t antigens.
Large T-antigen (Tag) binds to and functionally inactivates both p53 and Rb (Mietz et al., 1992; Ludlow, 1993) , thus generating a tissue-specific functional knockout of these two critical tumor suppressor genes.
In addition to providing tumor tissue that has been generated through defined initiating genetic changes, certain mouse models offer an additional advantage of progressing through well-defined, stage-specific changes during tumor progression. This offers the opportunity to study the accumulation of molecular changes as tumors progress through various stages, which is not easily performed in studies involving human samples.
The goals of these microarray studies are to 1) determine what sets of genes may be commonly involved in cancer development in the mammary gland; 2) what sets of genes define tumors which have formed in response to a particular oncogenic stimulus; and 3) how the expression profiles of mouse cancer models compare to gene expression profiles of human breast tumors. This information is directly relevant to understanding mammary neoplasia from the perspective of toxicologic pathology. EXPERIMENTAL APPROACH Tumors from several genetically engineered mouse models of mammary cancer were collected including MMTVmyc (Stewart et al., 1984) , MMTV-ras (Sinn et al., 1987) , MMTV-PyMT (Guy et al., 1992) , MMTV-her2/neu (Muller et al., 1988) , C3(1)-Tag (Maroulakou et al., 1994) , WAP-Tag (Li et al., 1996) . All mice were of the same FVB/N background. At least 5 individual tumors from 5 separate female mice were analyzed. Tumors were collected when they were approximately 1-cm in diameter and did not appear necrotic or cystic. Mammary tissue from normal virgin 12-week-old FVB/N female mice was used as the control to produce reference RNA for the competitive hybridizations. Reference RNA was generated by pooling multiple mammary glands from at least 20 individual animals to normalize for biologic variability and estrous status, whereas tumor RNA was generated from individual tumors . Integrity of RNA was confirmed by gel electrophoresis. Probe was generated from tumor RNA incorporating Cy5 labeling and control reference probe was generated using Cy3 labeling.
Microarray analysis was performed using 2 separate cDNA microarrays, the NCI ATC mouse array containing approxi-mately 2.7 K features and an array containing approximately 9 K features from the Incyte GEM1 clone set. Data was uploaded to the NCI madB microarray server and analyzed using several analytic tools.
In order to confirm the microarray results, the expression levels of several representative genes were validated by either Nothern blot analysis, RT-PCR or Western blot analysis.
RESULTS AND DISCUSSION
Identification of Genes Commonly Dysregulated in Mammary Cancer Models: The first level of analysis determined which genes were commonly up-or down-regulated by at least 2-fold in all of the mammary cancer models. Since the common reference RNA was normal mammary gland tissue, this analysis should give some insight into genes that may be critical for altering pathways involved in normal cell growth regulation, including pathways involved in cell cycle regulation and apoptosis. Out of the approximately 9,000 genes analyzed on the arrays, 900 were found to be commonly altered in tumors from the various mammary tumor models . Figure 1 provides a breakdown of these genes according to their known functions. As depicted in Figure 1 , the majority of the genes (57%) are represented by ESTs with unknown function, suggesting that the functions of many new genes associated with mammary cancer need to be determined. The remaining 43% of the genes are named genes which represent all major classes of cellular function.
However, an important technical issue to be considered is that the normal mammary gland tissue used as the control reference RNA is composed of multiple cell types, including not only mammary epithelial cells, but also adipose tissue and stromal cell types. The mammary tumor tissue is composed primarily of epithelial cells with relatively few adipose cells as well as stromal cells including a significant endothelial cell component. Since the comparison between the tumor and normal tissue does not compare exactly the same cell types in the same proportion, interpretation of the array results must remain qualified until additional studies determine in which cell type(s) the expression changes occur. We are currently performing such studies by selectively isolating epithelial or stromal cells during tumorigenesis through the use of laser capture microscopy. This powerful technique allows one to harvest individual cells based upon their morphologic appearance and then process the RNA for microarray studies. This approach will lead to a much more thorough understanding of expression changes that occur are various stages of tumor progression, as well as the genetic cross-talk between stromal and epithelial cells.
The list of genes commonly altered in the mammary tumor models may be especially useful for identifying therapeutic targets that might be efficacious against cancers with varied genetic aberrations. This could include both specific molecular pathways as well as cell surface proteins that might be particularly useful targets for immunotherapeutic approaches. While the identification of the commonly dysregulated genes in the various mammary cancer models provides important new insights into previously unrecognized genes involved in oncogenesis, we were also interested in identifying clusters of genes that may be signatures for particular oncogenic pathways, especially those known to be altered in human breast cancer. In order to accomplish this, a second approach was used.
Identification of Gene Expression Changes Based Upon the Initiating Oncogenic Event:
In order to identify genes whose expression differed between tumors from the various transgenic models, we employed an F-test analysis. This type of statistical analysis determined the genes whose variance in expression was significantly different between each group of tumor models. Since the mouse models were previously classified on the basis of the transgene, this analysis was supervised.
The results of this analysis of variance determined that the expression of a set of approximately 900 genes were significantly different between the tumor types . Hierarchical clustering of the tumors using this gene set revealed that the first degree of separation between the tumors models distinguished the nuclear oncogenes Tag and myc from the extranuclear oncogene signaling pathways ras, her2/neu, and PyMT (Figure 2) . Additionally, many subclusters often represented expression levels characteristic for a particular tumor model or group of models. The number of genes whose expression was characteristic for a particular tumor type is depicted in Figure 2 .
Tag by far had the highest number of genes (170) whose expression was unique to this oncogene. The genes identi-fied in the Tag clusters involved numerous cellular pathways (Figure 3) , demonstrating that at least at the late stage of tumorigenesis in Tag cancers, a vast number of cellular pathways have been dysregulated. Ninety-two genes also demonstrated a similar pattern of expression in both the Tag and myc models. The other models had expression changes that were unique, although much smaller number of genes. The ras/her2/PyMT models had a significant overlap of genes that were commonly dysregulated . Interestingly, no expression change was specific for PyMT. Infact, unlike the other tumor models, more genes appeared to be down-regulated in the PyMT tumors than were up-regulated. Some of the highlights of the signature genes for each oncogenic pathway are presented in Table 2 .
Changes in Gene Expression During Tumor Progression:
Identifying stage-specific changes in gene expression during the evolution of mammary cancer is critical to understanding what sequence of genetic events are important for tumor progression. Our laboratory has been performing laser capture microscopy at different stages of tumor progression in the C3(1)/Tag model that progresses through well-defined stages of tumor formation, including the development of mammary intraepithelial neoplasia (MIN), a lesion that histologically resembles human ductal carcinoma in situ (Figure 3) . Early results indicate that the vast majority of expression changes FIGURE 2.-Identification of genes most differentially expressed between the tumors models. Analysis of variance using the F-test method identified 930 genes in this category. The number of genes whose altered expression were uniquely associated with particular tumor type are depicted for each tumor type or groups of tumor types. occur at stages which precede MIN formation (Y. Ye, unpublished data). Ongoing studies will further define the temporal changes in gene expression which occur during tumor progression, both in the epithelial cells as well as in the neighboring stromal tissue. This information will have significant implications for predicting whether certain early lesions will progress, and may identify new targets for early intervention or chemoprevention.
Comparison Between Mouse and Human Data:
A direct comparison between mouse and human microarray data is currently not possible since there is no common reference RNA between the species . The histology of normal mouse and human mammary glands are quite different and can not serve as comparable reference samples for this type of comparison. Additional informatics approaches are being developed to overcome this problem. Currently, we are analyzing informative sets of genes identified by clustering algorithms to determine whether a given gene cluster that segregates tumors from one species can also be used to segregate tumors from the other species. If such sets of genes are identified, this would provide important initial insights into how similar oncogenic mechanisms may be operating in both species. Early analyses have determined that the cluster of genes associated with proliferation of the human tumors with the basal cell phenotype (Sorlie et al., 2001) are also highly up-regulated in the mouse mammary tumors generated through the overexpression of Tag (K. Desai, unpublished data). However, it is likely that this approach will be of limited value. As an alternative approach, we are developing algorithms which may allow us to directly, but artificially, normalize array data between species. If this approach proves useful, a much more precise comparison of array data between species will be possible. This information would provide the most accurate way to compare gene expression profiles between human disease and the models created to represent them.
FUTURE DIRECTIONS
The generation of these gene expression data sets provides a basis for determining which mammary cancer models may untilize a particular signaling pathway or express a particular molecular target. Thus, this data may be helpful in identifying a model appropriate for studying particular experimental questions (Desai et al., 2002a (Desai et al., , 2002b Kavanaugh et al., 2002) . For instance, a specific molecular target or pathway may be most appropriately expressed in a particular model for performing preclinical studies with novel compounds.
Recently, additional studies have been performed on mammary tumors from mouse models in which p53 or BRCA1 has been deleted ( Figure 4 ). Array analyses of these models is demonstrating that they have unique signature expression patterns which differ from the previously studied models. Since these models have tremendous relevance to particular forms of human breast cancer, additional analyses may identify aberrations in expression that are similar between both the mouse models and human breast cancers that harbor similar mutations. New informatics approaches being developed in our lab will aid in this critical intraspecies comparison. Ultimately, such analyses will lead to a deeper understanding of oncogenic mechanisms and the molecular similarities or differences between the human disease and the animal models that have been generated to represent human breast cancer.
Recent studies in our lab have also demonstrated the potential utility of gene expression profiling to uncover pathways involved in chemoprevention or therapeutic responses in vivo (C. Kavanaugh, unpublished data; A. Calvo, unpublished data) . These approaches will broaden our knowledge of how certain chemopreventive agents may work and will hopefully identify additional therapeutic targets to inhibit tumor formation or progression. Similarly, a more thorough understanding of the gene expression changes in response to potential toxicologic agents will help to more precisely define mechanisms of toxicologic injury that may be involved in carcinogenesis.
